Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While this isn’t the end of giant pharmaceutical companies, there is a new generation of biotechs that have been able to advance rapidly due to the massive advances in computer technology in recent decades. These A-r...
The following slide deck was published by IVERIC bio, Inc. in conjunction with this event. For further details see: IVERIC (ISEE) Investor presentation - Slideshow
The following slide deck was published by IVERIC bio, Inc. in conjunction with this event. For further details see: IVERIC bio (ISEE) Investor Presentation - Slideshow
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:40 a.m. ET. An audio ...
Image source: The Motley Fool. IVERIC bio, Inc. (NASDAQ: ISEE) Q3 2021 Earnings Call Nov 09, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: IVERIC bio, Inc. (ISEE) Q3 2021 Earnings Call Transcript
The following slide deck was published by IVERIC bio, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: IVERIC bio, Inc. 2021 Q3 - Results - Earnings Call Presentation
IVERIC bio, Inc. (ISEE) Q3 2021 Earnings Conference Call November 9, 2021 08:00 ET Company Participants Kathy Galante - Senior Vice President of Investor Relations Glenn Sblendorio - Chief Executive Officer Keith Westby - Chief Operating Officer Pravin Dugel - President David Carroll - Chief ...
IVERIC bio (NASDAQ:ISEE): Q3 GAAP EPS of -$0.23 beats by $0.06. Cash, cash equivalents and marketable securities as of September 30, 2021 of $241.97M Press Release For further details see: IVERIC bio EPS beats by $0.06
- Zimura ® GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% - - Preparations of a New Drug Application (NDA) and Building Commercial Infrastructure are Underway for a Potential Launch of Zimura for ...
IVERIC bio (NASDAQ:ISEE) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.26. Recently, the company priced its upsized public offering of 9M shares of common stock at $16.75/share with expected gross proceed...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...